Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Rapid single B cell antibody discovery using nanopens and structured light.

Winters A, McFadden K, Bergen J, Landas J, Berry KA, Gonzalez A, Salimi-Moosavi H, Murawsky CM, Tagari P, King CT.

MAbs. 2019 Aug/Sep;11(6):1025-1035. doi: 10.1080/19420862.2019.1624126. Epub 2019 Jun 11.

2.

Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates.

Walker KW, Salimi-Moosavi H, Arnold GE, Chen Q, Soto M, Jacobsen FW, Hui J.

PLoS One. 2019 May 23;14(5):e0217061. doi: 10.1371/journal.pone.0217061. eCollection 2019.

3.

Engineering NaV1.7 Inhibitory JzTx-V Peptides with a Potency and Basicity Profile Suitable for Antibody Conjugation To Enhance Pharmacokinetics.

Murray JK, Wu B, Tegley CM, Nixey TE, Falsey JR, Herberich B, Yin L, Sham K, Long J, Aral J, Cheng Y, Netirojjanakul C, Doherty L, Glaus C, Ikotun T, Li H, Tran L, Soto M, Salimi-Moosavi H, Ligutti J, Amagasu S, Andrews KL, Be X, Lin MJ, Foti RS, Ilch CP, Youngblood B, Kornecook TJ, Karow M, Walker KW, Moyer BD, Biswas K, Miranda LP.

ACS Chem Biol. 2019 Apr 19;14(4):806-818. doi: 10.1021/acschembio.9b00183. Epub 2019 Mar 27.

PMID:
30875193
4.

Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice.

Mao K, Quipildor GF, Tabrizian T, Novaj A, Guan F, Walters RO, Delahaye F, Hubbard GB, Ikeno Y, Ejima K, Li P, Allison DB, Salimi-Moosavi H, Beltran PJ, Cohen P, Barzilai N, Huffman DM.

Nat Commun. 2018 Jun 19;9(1):2394. doi: 10.1038/s41467-018-04805-5.

5.

Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability.

Jacobsen FW, Stevenson R, Li C, Salimi-Moosavi H, Liu L, Wen J, Luo Q, Daris K, Buck L, Miller S, Ho SY, Wang W, Chen Q, Walker K, Wypych J, Narhi L, Gunasekaran K.

J Biol Chem. 2017 Feb 3;292(5):1865-1875. doi: 10.1074/jbc.M116.748525. Epub 2016 Dec 19.

6.

A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair.

Florio M, Gunasekaran K, Stolina M, Li X, Liu L, Tipton B, Salimi-Moosavi H, Asuncion FJ, Li C, Sun B, Tan HL, Zhang L, Han CY, Case R, Duguay AN, Grisanti M, Stevens J, Pretorius JK, Pacheco E, Jones H, Chen Q, Soriano BD, Wen J, Heron B, Jacobsen FW, Brisan E, Richards WG, Ke HZ, Ominsky MS.

Nat Commun. 2016 May 27;7:11505. doi: 10.1038/ncomms11505.

7.

A multifactorial screening strategy to identify anti-idiotypic reagents for bioanalytical support of antibody therapeutics.

Salimi-Moosavi H, Winters A, Abbott C, Patel J, Hager T, Patel V, Shih J, Zhuang Y, Ma M.

Anal Biochem. 2015 Feb 1;470:52-60. doi: 10.1016/j.ab.2014.10.007. Epub 2014 Oct 27.

PMID:
25447458
8.

Inhibition of CRAC with a human anti-ORAI1 monoclonal antibody inhibits T-cell-derived cytokine production but fails to inhibit a T-cell-dependent antibody response in the cynomolgus monkey.

Gaida K, Salimi-Moosavi H, Subramanian R, Almon V, Knize A, Zhang M, Lin FF, Nguyen HQ, Zhou L, Sullivan JK, Wong M, McBride HJ.

J Immunotoxicol. 2015 Apr-Jun;12(2):164-73. doi: 10.3109/1547691X.2014.915897. Epub 2014 Jul 3.

PMID:
24990272
9.

Evaluating the impact of matrix effects on biomarker assay sensitivity.

Thway T, Salimi-Moosavi H.

Bioanalysis. 2014 Apr;6(8):1081-91. doi: 10.4155/bio.14.55.

PMID:
24830892
10.

A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates.

Cooke KS, Hinkle B, Salimi-Moosavi H, Foltz I, King C, Rathanaswami P, Winters A, Steavenson S, Begley CG, Molineux G, Sasu BJ.

Blood. 2013 Oct 24;122(17):3054-61. doi: 10.1182/blood-2013-06-505792. Epub 2013 Aug 14.

PMID:
23945155
11.

Novel anti-c-Mpl monoclonal antibodies identified multiple differentially glycosylated human c-Mpl proteins in megakaryocytic cells but not in human solid tumors.

Zhan J, Felder B, Ellison AR, Winters A, Salimi-Moosavi H, Scully S, Turk JR, Wei P.

Monoclon Antib Immunodiagn Immunother. 2013 Jun;32(3):149-61. doi: 10.1089/mab.2012.0117.

PMID:
23750472
12.

Cytokines associated with increased erythropoiesis in Sprague-Dawley rats administered a novel hyperglycosylated analog of recombinant human erythropoietin.

Andrews DA, Hamadeh HK, He YD, Boren BM, Turk JR, Boyce RW, Mytych DT, Barger TE, Salimi-Moosavi H, Sloey B, Elliott S, McElroy P, Sinclair AM, Shimamoto G, Pyrah IT, Lightfoot-Dunn RM.

Toxicol Pathol. 2014;42(3):540-54. doi: 10.1177/0192623313486318. Epub 2013 May 14.

PMID:
23674392
13.

Dose-related differences in the pharmacodynamic and toxicologic response to a novel hyperglycosylated analog of recombinant human erythropoietin in Sprague-Dawley rats with similarly high hematocrit.

Andrews DA, Boren BM, Turk JR, Boyce RW, He YD, Hamadeh HK, Mytych DT, Barger TE, Salimi-Moosavi H, Sloey B, Elliott S, McElroy P, Sinclair AM, Shimamoto G, Pyrah IT, Lightfoot-Dunn RM.

Toxicol Pathol. 2014;42(3):524-39. doi: 10.1177/0192623313486319. Epub 2013 May 14.

PMID:
23674391
14.

Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities.

Hager T, Spahr C, Xu J, Salimi-Moosavi H, Hall M.

Anal Chem. 2013 Mar 5;85(5):2731-8. doi: 10.1021/ac303203y. Epub 2013 Feb 19.

PMID:
23373459
15.

Simultaneous analysis of multiple monoclonal antibody biotherapeutics by LC-MS/MS method in rat plasma following cassette-dosing.

Li H, Ortiz R, Tran LT, Salimi-Moosavi H, Malella J, James CA, Lee JW.

AAPS J. 2013 Apr;15(2):337-46. doi: 10.1208/s12248-012-9435-5. Epub 2012 Dec 12.

16.

Inhibition of WISE preserves renal allograft function.

Qian X, Yuan X, Vonderfecht S, Ge X, Lee J, Jurisch A, Zhang L, You A, Fitzpatrick VD, Williams A, Valente EG, Pretorius J, Stevens JL, Tipton B, Winters AG, Graham K, Harriss L, Baker DM, Damore M, Salimi-Moosavi H, Gao Y, Elkhal A, Paszty C, Simonet WS, Richards WG, Tullius SG.

J Am Soc Nephrol. 2013 Jan;24(1):66-76. doi: 10.1681/ASN.2012010012. Epub 2012 Nov 26.

17.

Bioanalysis of target biomarker and PK/PD relevancy during the development of biotherapeutics.

Lee JW, Salimi-Moosavi H.

Bioanalysis. 2012 Oct;4(20):2513-23. doi: 10.4155/bio.12.220. Review.

PMID:
23157359
18.

Implementation of a universal analytical method in early-stage development of human antibody therapeutics: application to pharmacokinetic assessment for candidate selection.

Shih JY, Patel V, Watson A, Hager T, Luan P, Salimi-Moosavi H, Ma M.

Bioanalysis. 2012 Oct;4(19):2357-65. doi: 10.4155/bio.12.201.

PMID:
23088462
19.

Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure.

Bautista AC, Salimi-Moosavi H, Jawa V.

AAPS J. 2012 Dec;14(4):843-9. doi: 10.1208/s12248-012-9403-0. Epub 2012 Sep 1.

20.

Rapid affinity measurement of protein-protein interactions in a microfluidic platform.

Salimi-Moosavi H, Rathanaswami P, Rajendran S, Toupikov M, Hill J.

Anal Biochem. 2012 Jul 15;426(2):134-41. doi: 10.1016/j.ab.2012.04.023. Epub 2012 Apr 26.

PMID:
22542978
21.

General LC-MS/MS method approach to quantify therapeutic monoclonal antibodies using a common whole antibody internal standard with application to preclinical studies.

Li H, Ortiz R, Tran L, Hall M, Spahr C, Walker K, Laudemann J, Miller S, Salimi-Moosavi H, Lee JW.

Anal Chem. 2012 Feb 7;84(3):1267-73. doi: 10.1021/ac202792n. Epub 2012 Jan 25.

PMID:
22243404
22.

Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury.

Li X, Grisanti M, Fan W, Asuncion FJ, Tan HL, Dwyer D, Han CY, Yu L, Lee J, Lee E, Barrero M, Kurimoto P, Niu QT, Geng Z, Winters A, Horan T, Steavenson S, Jacobsen F, Chen Q, Haldankar R, Lavallee J, Tipton B, Daris M, Sheng J, Lu HS, Daris K, Deshpande R, Valente EG, Salimi-Moosavi H, Kostenuik PJ, Li J, Liu M, Li C, Lacey DL, Simonet WS, Ke HZ, Babij P, Stolina M, Ominsky MS, Richards WG.

J Bone Miner Res. 2011 Nov;26(11):2610-21. doi: 10.1002/jbmr.472.

23.

Bioanalytical approaches to quantify "total" and "free" therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development.

Lee JW, Kelley M, King LE, Yang J, Salimi-Moosavi H, Tang MT, Lu JF, Kamerud J, Ahene A, Myler H, Rogers C.

AAPS J. 2011 Mar;13(1):99-110. doi: 10.1208/s12248-011-9251-3. Epub 2011 Jan 15. Review.

24.

Novel approaches using alkaline or acid/guanidine treatment to eliminate therapeutic antibody interference in the measurement of total target ligand.

Salimi-Moosavi H, Lee J, Desilva B, Doellgast G.

J Pharm Biomed Anal. 2010 Apr 6;51(5):1128-33. doi: 10.1016/j.jpba.2009.11.021. Epub 2009 Dec 3.

PMID:
20022440
25.

An in vivo platform for translational drug development in pancreatic cancer.

Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, Shi C, Danenberg K, Danenberg PV, Kuramochi H, Tanaka K, Singh S, Salimi-Moosavi H, Bouraoud N, Amador ML, Altiok S, Kulesza P, Yeo C, Messersmith W, Eshleman J, Hruban RH, Maitra A, Hidalgo M.

Clin Cancer Res. 2006 Aug 1;12(15):4652-61.

26.

Protein separation and surfactant control of electroosmotic flow in poly(dimethylsiloxane)-coated capillaries and microchips.

Badal MY, Wong M, Chiem N, Salimi-Moosavi H, Harrison DJ.

J Chromatogr A. 2002 Feb 22;947(2):277-86.

PMID:
11883661
27.

A multireflection cell for enhanced absorbance detection in microchip-based capillary electrophoresis devices.

Salimi-Moosavi H, Jiang Y, Lester L, McKinnon G, Harrison DJ.

Electrophoresis. 2000 Apr;21(7):1291-9.

PMID:
10826672

Supplemental Content

Loading ...
Support Center